The Hematology Oncology Pharmacy Association (HOPA) is hosting the HOPA Policy Summit on Drug Waste in the Treatment of Cancer with health care professionals and industry members.
Hematology
Latest News
Advertisement
CME Content
Advertisement
The Hematology Oncology Pharmacy Association (HOPA) is hosting the HOPA Policy Summit on Drug Waste in the Treatment of Cancer with health care professionals and industry members.
Top news of the week in oncology and cancer drug development.
Methotrexate oral solution (Xatmep) indicated to treat pediatric patients.
Midostaurin demonstrated a statistically significant improvement in overall survival among AML patients.
Midostaurin (Rydapt) approved to treat acute FLT3 mutation positive acute myeloid leukemia.
Stivarga expanded to include the treatment of hepatocellular carcinoma in patients previously treated with sorafenib.
Stivarga is the first FDA-approved treatment for hepatocellular carcinoma in almost a decade.
Top news of the week in oncology and cancer drug development.
Findings could help improve treatment efficacy for patients with ALL.
Multiple myeloma survivor seeks to empower patients by illustrating the value of human life.
Protein determines whether breast cancer cells become resistant to tamoxifen.
The activation of the STAT5 protein linked to acute lymphoblastic leukemia.
Polymer capsules that could play a key role in delivering targeted cancer therapies.
Top news of the week in oncology and cancer drug development.
Top news of the week in oncology and cancer drug development.
Hodgkin lymphoma cancer survivors are 2.4 times more likely to develop a second type of cancer.
Study identifies potential Achilles heel of kinase-driven cancers.
Treatment with endostatin slowed the proliferation of resistant prostate cancer cells.
Most models were cancer-free within 6 weeks of treatment with selenomab-drug conjugates.
Next-generation antibody treatments effectively deliver cytotoxic drugs to tumors.
Corticosteroids, chemotherapy, and immunotherapy may all be used to treat castration-resistant prostate cancer.
Top news of the week in oncology and cancer drug development.
Checkpoint inhibitors plus myeloid-derived suppressor cell inhibitors show promise as prostate cancer treatment.
Quiescent stem cells are dormant and are not impacted by cancer treatments.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bepirovirsen Shows Breakthrough Potential for Functional Cure in Chronic Hepatitis B
2
New Federal Dietary Guidelines Emphasize Protein and Real Foods While Cutting Sugar
3
FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan
4
'High-Stakes Headaches': Why Pharmacists May be Key to Better Headache Management
5